Not long after Novo Nordisk received an untitled letter from the FDA disputing certain elements of the first TV spot for its ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

Vanda Pharmaceuticals’ seven-year ambition to score a coveted label expansion for sleep drug Hetlioz has taken an unusual turn, with the FDA acquiescing to a formal hearing on the matter. | The ...

Collegium Pharmaceutical has tapped an appropriately glitzy star as the face of a new campaign spotlighting the bright side of life with attention-deficit/hyperactivity disorder (ADHD). | Collegium ...

Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. | The primary growth drivers in Bayer’s pharma sector—Nubeqa and ...

With a substantial manufacturing base already locked down in China, CRDMO BioDuro is taking a short jaunt down to Taiwan for its latest drug ingredients production play.  | BioDuro, headquartered in ...

One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...

Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago.

Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s ...

Acadia Pharmaceuticals isn’t taking its recent rejection from the European Medicines Agency lying down, vowing to seek a ...

In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Kraemer discussed how patients inspire his work, his advice for industry veterans and how he unwinds on the fairway.